Tekmira Pharmaceuticals (TKMR), which is working to develop an Ebola vaccine, is up 32% in pre-market hours at $27.50 on reports that the first case of the disease has been diagnosed in the U.S.
As it has been already reported, the first U.S. Ebola case was confirmed by The Centers for Disease Control, which said a patient being treated at a hospital in Dallas, TX tested positive for the disease. The FDA has authorized the use of Tekmira’s TKM-EBOLA under an expanded access protocol in individuals that are already infected with Ebola virus.
Tekmira Pharmaceuticals, currently valued at $457M, has a median Wall Street price target of $25.00 with a high target of $31.00. Approximately 5,401,036 shares changed hands during Tuesday’s trading session compared to the stock’s average daily volume of 3,581,340.
In the past 52 weeks, shares of Canadian drugmaker have traded between a low of $6.93 and a high of $31.48. TKMR currently prints a one year return of about 204% and a year-to-date return of around 165.24%.
Tekmira has a Relative Strength Index (RSI) and MACD indicator of 54.36 and -0.11, respectively.
Another stock moving in reaction to the Ebola news is Biocryst Pharmaceuticals (BCRX). Ticker declined for the majority of Tuesday’s session and closed down by 71 cents at $9.78. In premarket-hours however, the stock is up 9% changing hands at $10.60.
BioCryst Pharmaceuticals has a PEG and t-12 price-to-sales ratio of (1.76) and 39.25, respectively. EPS registers at ($0.64). Currently there are 11 analysts that rate BCRX a ‘Buy’, 1 rates it a ‘Hold’. No analysts rate it a ‘Strong Buy’ or a ‘Sell’. BCRX has a median Wall Street price target of $18.00 with a high target of $24.00.
In the past 52 weeks, shares of Durham, North Carolina-based firm have traded between a low of $4.55 and a high of $14.62 and are now at $10.60. Shares are up 34.34% year-over-year and 28.68% year-to-date.
The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.
Lakeland Industries, Inc. (LAKE) is another Ebola play. While ticker is not part of the biopharma sector, it is involved in manufacturing personal protective equipment to protect healthcare workers in Ebola areas.
Lakeland Industries is up $0.94, or 13.53%, to $7.89 in pre-market trading today. Approximately 76,775 shares changed hands duriing Tuesday’s trading session, compared to the stock’s average daily volume of 65,389 shares.
On valuation-measures, shares of Lakeland have a price/book and t-12 profit margin of 0.83 and (4.12%), respectively. EPS is ($0.65). The company has a market cap of $37.25M.
On trading-measure, LAKE has a beta of 0.06 and a short float of 0.17%. In the past 52 weeks, shares of the safety garments and accessories manufacturer have traded between a low of $4.75 and a high of $9.40 with the 50-day MA and 200-day MA located at $6.58 and $6.78 levels, respectively.
LAKE currently prints a one year return of about 28.70% and a year-to-date return of around 32.13%.
The chart below shows where the equity has traded over the last 52 weeks, with the 50-day and 200-day MAs included.
Angie’s List Inc (ANGI) was upgraded by Northland Capital from an ‘Under Perform’ rating to a ‘Market Perform’ rating in a research note issued on Wednesday. The upgrades follows an FT report suggesting the company has hired bankers to explore alternatives, including sale.
Angie’s List shares, which recently traded up 16.17%, have a PEG and forward P/E ratio of -0.76 and 127.40, respectively. Price/Sales for the same period is 1.33 while EPS is ($0.56). Currently there are 5 analysts that rate ANGI a ‘Buy’, 11 rate it a ‘Hold’. 1 analyst rates it a ‘Sell’. ANGI has a median Wall Street price target of $12.00 with a high target of $15.00.
In the past 52 weeks, shares of Indianapolis, Indiana-based company have traded between a low of $6.28 and a high of $21.32 and are now at $7.40. Shares are down 71.68% year-over-year and 57.95% year-to-date.